Walter E. Washington Convention Center
Washington, D.C.
May 16-19, 2022

Lovelace Biomedical  

Albuquerque,  NM 
United States
https://www.lovelacebiomedical.org
  • Booth: 558


Meet with Janet Benson at Booth #558 - Gene Therapy Expert

Lovelace Biomedical is a nonclinical contract research laboratory with expertise in expertise in toxicology, gene/cell therapy, neurological disorders, infectious disease, medical countermeasures, respiratory drug development and bioanalytical chemistry. 


 Videos

Lovelace Biomedical Gene Therapy

 Products

  • Gene Therapy
    Lovelace Biomedical is the leading CRO for performing Gene Therapy nonclinical development....

  • Lovelace Biomedical is the leading CRO for performing Gene Therapy nonclinical development. We have been working with the FDA and scientists with leading pioneers in the industry to advance gene therapy products to the clinic. In 2007 our Gene Therapy pharmacology/toxicology Center was established by the NIH along with pioneers at the University of Pennsylvania. We have maintained this core for over 12 years, and have built on its foundation a successful resource for biotechnology and pharmaceutical companies aiming to advance their candidates from discovery to clinical stage by GLP enabling studies as rapidly as possible.
  • Janet Benson - Scientist Emeritus
    Dr. Benson has been a toxicologist at Lovelace for 40 years. As Co-PI of the Pharmacology/Toxicology Core for the NHLBI GTRP, she consults with investigators in developing their pre-IND packages for preclinical therapy development....

  • Dr. Benson has been a toxicologist at Lovelace for 40 years and currently has Emeritus Status.  She has investigated the toxicity, PK, or biodistribution of metals, solvents, polymers, natural products, select agents, vesicants and gene therapeutics.  She has evaluated the efficacy of a variety of pharmaceuticals to prevent pulmonary, ocular and cutaneous diseases.  She has managed over 10 complex, multiyear contracts or grants with the government (Department of Energy, National Toxicology Program, National Institute of Allergy and Infectious Diseases [NIAID], National Institute of Environmental Health Science [NIEHS], and the current GTRP contract for NHLBI) as well as for industry consortia.  She has extensive experience conducting studies under GLP Guidelines.  As Co-PI of the Pharmacology/Toxicology Core for the NHLBI GTRP, she consults with investigators in developing their pre-IND packages for preclinical therapy development. 

    Dr. Benson holds a BS degree in Chemistry from the University of California, Berkeley and a PhD in Comparative Pharmacology and Toxicology from UC, Davis.  She was a Diplomate of the American Board of Toxicology from 1981 - 2017.  She has over 100 publications in the scientific literature, has served on scientific advisory Committees (National Academy of Sciences, the EPA IRIS review committee, and American Conference of Industrial Hygienists Threshold Limit Value Committee) and currently serves as a member of the Scientific Advisory Committee for the US Transuranium and Uranium Registries.  She is an active member of the American Society for Gene and Cellular Therapy.

  • Jane Lindborg - Study Director
    Dr. Jane Lindborg is a Study Director at Lovelace Biomedical with specialized training in gene therapy and neuroscience....

  • Dr. Jane Lindborg is a Study Director at Lovelace Biomedical with specialized training in gene therapy and neuroscience.  She holds a BS degree in Chemistry from the University of Puget Sound and a PhD in Neuroscience from Case Western Reserve University, and has completed a Postdoctoral appointment at Yale in gene therapy applied to neurological models.  At Lovelace, Dr. Lindborg conducts neuropharmacology and toxicology studies with both rodents and nonhuman primates. She has experience conducting studies under GLP Guidelines and has managed both government and industry contracts.